Autoimmune Diseases  >>  ceralifimod (ONO 4641)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ceralifimod (ONO 4641) / Ono Pharma
DreaMS, NCT01081782 / 2009-014339-19: A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

Checkmark AAN 2014: Multiple sclerosis (DREAMS)
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (DREAMS)
Checkmark Data - ENS 2012
May 2012 - May 2012: Data - ENS 2012
Checkmark Data
More
Completed
2
407
Japan, US, Canada, Europe, RoW
ONO-4641, ONO-4641 placebo
Ono Pharma USA Inc
Multiple Sclerosis
12/11
12/11
DreaMS, NCT01226745 / 2010-018705-11: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Checkmark ECTRIMS 2013: Multiple sclerosis
Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis
Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Terminated
2
340
Japan, US, Canada, Europe, RoW
ONO-4641, MSC2430913A, Ceralifimod
EMD Serono, Merck KGaA, Darmstadt, Germany, Ono Pharmaceutical Co. Ltd
Multiple Sclerosis
01/15
01/15

Download Options